3628 results for «382»
3628 results
Expanding horizons in coronary calcified lesion management with intravascular lithotripsy
10 Oct 2025 – From AICT-AsiaPCR 2025
This session highlights advancements in managing coronary calcified lesions through intravascular lithotripsy using the Shockwave system. It discusses the unique mechanism of action for different calcium morphologies, reviews the latest clinical data, and addresses complex scenarios including diffuse lesions and challenging nodular or eccentric calcium deposits,...
Redefining precision and performance in TAVI: advancing clinical outcomes with the Evolut FX+ system
10 Oct 2025 – From AICT-AsiaPCR 2025
Delve into advanced transcatheter aortic valve implantation (TAVI) with the Evolut FX plus system, focusing on its application in patients with small annulus and coronary artery disease (CAD). This session details step-by-step deployment, patient selection, imaging analysis, and highlights the distinctions from the previous Evolut R...
Drug-coated balloons: a PREVAIL-ing gamechanger in complex PCI
11 Oct 2025 – From AICT-AsiaPCR 2025
Focus on the evolving role of drug-coated balloons (DCB) in complex PCI, extending their use beyond traditional indications to challenging coronary lesions and high-risk patient populations. This session reviews clinical data from the SCAAR Prevail registry and discusses the evidence journey supporting broader advocacy for DCB...
OPTIMUM: Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients with Multivessel or Left Main Coronary Artery Disease
04 Nov 2021
Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.
Author
POPular PAUSE TAVI - Continuation or interruption of oral anticoagulation during TAVI?
02 Sep 2024
Luis Ortega-Paz provides his take on the POPular PAUSE TAVI trial presented by Dirk Jan van Ginkel at the ESC Congress 2024 in London.
Author
Best of #AHA21 Scientific Sessions: coronary and valvular heart disease trials
14 Nov 2021
Vijay Kunadian provides summaries of study designs and findings in Interventional Cardiology released at the 2021 virtual edition of the American Heart Association Congress. View an infographic of the AVATAR late-breaking trial by Ali Nazmi Calik.
Author
ESC/EACTS Valvular Heart Disease Guidelines 2021: updates from the 2017 Guidelines
29 Aug 2021
There has been significant expansion in the field of structural heart diseases in the last couple of years, generating an extensive body of evidence and warranting an update to the 2017 Guidelines. Mirvat Alasnag provides an analysis of the updates included in this new document - a joint...
Author
Early intervention in patients with asymptomatic severe aortic stenosis and left ventricular myocardial fibrosis (EVOLVED)
30 Oct 2024
Ali Nazmi Calik provides his take on the EVOLVED trial presented by Marc Dweck at TCT 2024 in Washington.
Author
